Update information

Update information

October 2016: Recommendation 1.3.19 and table 1 were updated to remove reference to hip circumference percentile charts.

This guideline is an update of NICE guideline CG155 (published January 2013).

A new recommendation has been added on providing information about olanzapine when choosing antipsychotic medication for children and young people with a first episode of psychosis. This is marked as [new 2016]. The evidence has been reviewed and no change made to the recommended action in 1 recommendation on choosing antipsychotic medication for children and young people with a first episode of psychosis. This is marked as [2016].

Where recommendations end [2013], the evidence has not been reviewed since the original guideline.

Minor changes since publication

November 2022: Following a surveillance review, we removed the recommendation for research on the clinical and cost effectiveness of omega‑3 fatty acids in the treatment of children and young people considered to be at high risk of developing psychosis. For more information, see appendix A: summary of evidence from surveillance.

December 2021: Following a surveillance review we have updated recommendations 1.3.16 and 1.3.19 and the supplementary information table to say that either glycosylated haemoglobin (HbA1c) or fasting blood glucose may be used to test for diabetes in people taking antipsychotic medication. We have also added a link to NICE's guideline on babies, children and young people's experience of healthcare.

ISBN: 978-1-4731-1869-0

  • National Institute for Health and Care Excellence (NICE)